Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroendocrine Tumors × Interferon-alpha × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Carcinoma, Renal Cell 32 Kidney Neoplasms 25 Leukemia 24 Melanoma 20 Leukemia, Myeloid, Chronic-Phase 20 Multiple Myeloma 16 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16 Lymphoma 14 Neoplasms, Plasma Cell 12 Pancreatic Neoplasms 9 Lymphoma, Follicular 9 Neoplasms 7 Lymphoma, Mantle-Cell 7 Waldenstrom Macroglobulinemia 6 Leukemia, Myeloid, Acute 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Burkitt Lymphoma 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, Non-Hodgkin 5 Lymphoma, Large-Cell, Immunoblastic 5 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, B-Cell, Marginal Zone 5 Colorectal Neoplasms 5 Carcinoma, Hepatocellular 5 Urinary Bladder Neoplasms 4 Recurrence 4 Rectal Neoplasms 4 Lung Neoplasms 4 Leukemia, Myeloid, Accelerated Phase 4 Colonic Neoplasms 4

Interventions

lutetium Lu 177 dotatate 33 Everolimus 29 Magnetic Resonance Spectroscopy 13 lanreotide 12 gallium Ga 68 dotatate 12 Temozolomide 11 Octreotide 11 Capecitabine 11 Nivolumab 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 surufatinib 8 pembrolizumab 8 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 Sunitinib 7 Specimen Handling 7 amino-acid, glucose, and electrolyte solution 6 90Y-octreotide, DOTA-Tyr(3)- 6 pasireotide 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 Carboplatin 5 Bevacizumab 5 olaparib 4 avelumab 4 Somatostatin 4 Ipilimumab 4 Injections 4 Etoposide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02838342 2021-08-02

EPICentro

Centre Hospitalier Universitaire de Besancon

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡